Just in 👉data from SWOG Cancer Research Network 1216 trial in mHSPC#prostatecancer👉 PSA level at 3 and 7 months after starting ADT Rx are strongly prognostic of OS: It’s time to design de- or escalation trials based on response biomarkers. OPEN access👉 tinyurl.com/3azhpt4r OncoAlert UroToday.com

Thank you to Cancer Discovery for offering us the opportunity to publish our work, simultaneous with #AACR24 ! Grateful to Elizabeth McKenna for facilitating a thoughtful but rapid peer review process to get this out in time for the meeting.
In #kidneycancer , we have been fortunate to have…

Serial ctDNA testing from IMVIGOR11 (post cystectomy in muscle invasive bladder cancer) show that ctDNA-ve patients (n=171) with a minimum of 12months follow up have 10% relapse rates and almost no deaths #EAU24 . Do we need to give adjuvant therapy to those as such low risk?

Updated table of IO combos (ITT population) in front line mRCC after #ASCOGU24 . Has anything changed for you based on these data?

Fantastic news for patients! Congrats to the master practice changing leader Toni Choueiri, MD et al. Tom Powles Uromigos OncoAlert UroToday.com great discussion Pedro C Barata, MD MSc FACP ASCO #GU24 Kidney Cancer Shilpa Gupta Tian Zhang, MD, MHS Evan Hall Marinos Tsiatas Amanda Nizam, MD Sarah P. Psutka MD MS Daniel Lin

Emotional talk by Toni Choueiri, MD presenting the first phase 3 adjuvant RCC trial showing OS benefit. Clinical meaningful ⬆️ by Pembro use in intermediate/ high risk patients. A lot to discuss relative to other studies #GU24 Robert Motzer MD Marinos Tsiatas Yiannis Dimitriadis Petros Grivas eeoogek.gr

Avelumab first-line maintenance therapy for locally advanced/metastatic UC: Results from the real-world US PATRIOT-II study. Presentation by Petros Grivas University of Washington. #GU24 written coverage by Zach Klaassen Georgia Cancer Center bit.ly/49aGHuN ASCO

OS results from KEYNOTE-564 study of adjuvant pembrolizumab versus placebo for ccRCC
Toni Choueiri, MD #GU24

EV-302 Subgroup Analyses presented by Michiel van der Heijden #GU24 #blcsm ASCO

🔷 EV+P improved PFS & OS regardless of cisplatin-eligibility and PD-L1 expression
🔷EV+P improved PFS & OS regardless of presence of liver, visceral, or LN metastases
🔷 EV+P improved PFS and OS across all…

1st positive TKI+IO study in mCRPC adding another combo to our armamentarium! Proud to be among the authors! Congrats to all! Neeraj Agarwal, MD, FASCO Sumanta K. Pal, MD, FASCO Petros Grivas Tian Zhang, MD, MHS Guru P. Sonpavde, MD Yüksel Ürün MikaLion Uromigos OncoAlert European Association of Urology (EAU) ΕΟΠΕ UroToday.com Tom Powles

Heading to San Francisco for ASCO #GU24 . Petros Grivas Sumanta K. Pal, MD, FASCO Pavlos Msaouel Brian Rini, MD Tian Zhang, MD, MHS Vadim Koshkin MD Neeraj Agarwal, MD, FASCO Tom Powles Yüksel Ürün OncoAlert European Association of Urology (EAU) ESMO - Eur. Oncology ΕΟΠΕ Uromigos Andrea Apolo, M.D. Guru P. Sonpavde, MD joaquim bellmunt Elizabeth Plimack MD

JUST IN: U.S. FDA approved erdafitinib for metastatic urothelial carcinoma (mUC) w/FGFR3 alterations, post 1 line TX. Approval based on THOR trial in NEJM; led by ylt Gustave Roussy & #siefkerRadtke MD Anderson Cancer Center presented #ASCO23 ASCO

nejm.org/doi/full/10.10…

Link:…

Great presentation by Ekaterina Laukhtina on RARC vs ORC triggering great discussion! Sarah P. Psutka MD MS Ashish M. Kamat, MD, MBBS Prof Ananya💙 Alessia Cimadamore OncoAlert #BLADDR23 Mirrors of Medicine Daniele Raggi Bernadett Szabados Ignacio Duran UroToday.com Daniel Lin Joshua Meeks Dr. John Sfakianos Marinos Tsiatas Shilpa Gupta Sia Daneshmand, M.D.

Umberto Capitanio gives fantastic talk on RCC challenging dogmas across disciplines:Uro/Rad/Med Onc/imaging!
Neeraj Agarwal, MD, FASCO Shilpa Gupta Andrea Necchi Toni Choueiri, MD Philippe spiess ylt Yüksel Ürün Laurence Albiges Sumanta K. Pal, MD, FASCO Rana McKay Marinos Tsiatas Kidney Cancer Chiara Mercinelli Daniele Raggi

On November 9, 2023, European Medical Agency (EMA) approved Talazoparib + Enzalutamide combination for pts with mCRPC #prostatecancer based on results of Talapro-2 ph3 trial.👇Weblink 👉 tinyurl.com/233r8423 OncoAlert Prostate Cancer Foundation UroToday.com Advanced Prostate Cancer Consensus Conference Huntsman Cancer Institute

Congrats Pavlos! Well deserved!

Voting for the ASCO Election is now open. I am honored to be running as one of the candidates for the Board of Directors Undesignated Member seats.

Visit asco.org/election to learn more about the candidates and place your votes!

ASCO OncoAlert Oncology Brothers Dana-Farber

#proudmentor moment with Vassilios Tzortzis during #awardwinning oral presentation on postchemo #rplnd #testicularcancer by 🥇 #mentee Konstantinos Evmorfopoulos #urology resident University Thessaly at #EMUC23 European Association of Urology (EAU) ESMO - Eur. Oncology ΕΟΠΕ EOE/HUA ESOncology Ursula Vogl silke gillessen Kostas Dimitropoulos